Volume 87 Issue 35 | pp. 16-17 | Concentrates
Issue Date: August 31, 2009

Hengrui Gets Okay For U.S. Trials

Department: Business
Keywords: Hengrui, U.S. trials, retagliptin

Shanghai-based Hengrui Pharmaceuticals has obtained FDA’s approval to start Phase I human trials in the U.S. for retagliptin, a compound for treating type 2 diabetes. The company says it is the first China-based company to get a green light for U.S. testing of a small-molecule drug invented in China. Belonging to the same class of compounds as Merck & Co.’s sitagliptin drug, retagliptin is another type of dipeptidyl peptidase-4 inhibitor.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment